Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …

Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

PURPOSE Preclinical data suggest the combination of an anti–programmed death receptor
1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with …

We are currently witnessing a worldwide increase in the incidence of melanoma. Incidence
in Europe is about 25 cases per 100,000 population, while in Australia it reaches a rate of 60 …

Background Primary analysis of the phase 3 IMspire150 study showed improved
investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib …

Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …